对德克拉维西丁治疗斑块性牛皮的第三期和长期数据的审查
Nickoulet Babaei1, Dahyeon Kim1, Mireya Cervantes2
1Loma Linda University School of Medicine, Loma Linda, California, USA.
International journal of dermatology
|August 21, 2025
概括
杜克拉维西丁是一种口服选择性氨酸激酶2 (TYK2) 抑制剂,在全身牛皮治疗中显示出显著的疗效和良好的安全性. 长期研究证实了持续的益处,使其成为有效的口服替代生物药物.
科学领域:
- 皮肤病学
- 免疫学
- 药理学
背景情况:
- 牛皮是一种由特定细胞因子信号通路驱动的慢性炎症.
- 牛皮的全身治疗通常涉及生物药物或其他免疫调节剂.
- 需要有效的口服治疗,具有良好的安全性.
研究的目的:
- 审查口服选择性氨酸激酶2 (TYK2) 抑制剂deucravacitinib在全身牛皮治疗中的有效性和安全性.
- 评估III期临床试验的长期结果.
主要方法:
- 从第三阶段临床试验 (POETYK PSO-1,PSO-2,PSO-4) 和扩展研究的数据分析.
- 使用牛皮区域和严重程度指数 (PASI 75) 作为主要终点,比较deucravacitinib与安慰剂的疗效.
- 安全性和耐受性的评估,包括不良事件和严重不良事件.
主要成果:
- 与安慰剂和阿普雷米拉斯特相比,德克拉维西替尼的疗效更高,PASI 75响应率显著提高.
- 在连续治疗三年后观察到持续的疗效.
- 药物耐受性很好,严重不良事件,感染和重大心血管不良事件的发生率很低. 常见的不良反应包括鼻炎,上呼吸道感染和.
结论:
- 杜克拉维西丁是一种有效的口服治疗中度至重度牛皮,具有持续的疗效和良好的安全性.
- 它是目前生物疗法的可行的口服替代品.
- 需要进一步的研究,包括对IL-17和IL-23抑制剂进行对比,以确定它在牛皮治疗中的地位.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
687
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
687
Drug Administration and Therapy Phases: Overview
738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738


